NeuroPointDX
生物技术研究
Madison，WI 158 位关注者
Our NPDX ASD test may lead to an earlier diagnosis for children with autism spectrum disorder (ASD).
关于我们
NeuroPointDX, through its compound safety screening division Stemina Biomarker Discovery, has developed the leading metabolomics platform for identifying differences in metabolism in children with ASD and other neurological disorders. NeuroPointDX has discovered differences in small molecules in the blood of children with ASD that allow earlier diagnosis and more precise treatment of children across the spectrum. NeuroPointDX is validating these markers and bringing its diagnostic test to market through its ongoing clinical study the Children’s Autism Metabolome Project (CAMP).
- 网站
-
https://www.neuropointdx.com
NeuroPointDX的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Madison，WI
- 类型
- 私人持股
- 创立
- 2016
- 领域
- neurodevelopmental disorders、autism、metabolomics和diagnosis
地点
-
主要
获取路线
504 S. Rosa Rd. Suite 150
US，WI，Madison，53719